✦ LIBER ✦

3501 ORAL Capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC): a randomised phase III trial

✍ Scribed by Y. Kang; W. Kang; D. Shin; J. Chen; J. Xiong; J. Wang; M. Lichinitser; M. Philco; T. Suarez; J. Santamaría

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

721 ORAL Similar safety results of capec

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Capecitabine/cisplatin versus 5-fluorour

✍ Kang, Y.-K.; Kang, W.-K.; Shin, D.-B.; Chen, J.; Xiong, J.; Wang, J.; Lichinitse 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 331 KB

A prospective randomized phase III trial

✍ Kim, T.W.; Choi, S.J.; Ahn, J.H.; Bang, H.S.; Chang, H.M.; Kang, Y.K.; Lee, J.S. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 173 KB

P51 Randomised, single-centre, phase 2 t

✍ Y. Chi; J. Wang; Z. Zheng; A. Zhou; L. Yang; T. Qu; W. Jiang; S. Shi; Y. Sun; Y. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

617 POSTER Initial safety findings from

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB

6509 5-FU/l-LV (RPMI) versus S-1 as firs

✍ Sawaki, A.; Yamaguchi, K.; Nabeya, Y.; Sakai, Y.; Osanai, H.; Denda, T.; Furue, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB